Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Growth in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 353,879 shares, a growth of 22.2% from the March 15th total of 289,475 shares. Based on an average daily volume of 113,195 shares, the short-interest ratio is currently 3.1 days. Currently, 2.2% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALLR. Geode Capital Management LLC grew its stake in Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after purchasing an additional 16,729 shares in the last quarter. XTX Topco Ltd acquired a new position in Allarity Therapeutics during the second quarter worth $51,000. Jane Street Group LLC acquired a new position in Allarity Therapeutics during the second quarter worth $27,000. Private Advisor Group LLC acquired a new position in Allarity Therapeutics during the third quarter worth $441,000. Finally, Citadel Advisors LLC acquired a new position in Allarity Therapeutics during the third quarter worth $149,000. 11.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Wednesday, January 21st. Ascendiant Capital Markets upped their price target on shares of Allarity Therapeutics from $9.50 to $9.75 and gave the company a “buy” rating in a report on Friday, April 10th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.75.

Allarity Therapeutics Stock Performance

Shares of Allarity Therapeutics stock opened at $1.24 on Friday. The business’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.18. Allarity Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.35. The firm has a market cap of $19.62 million, a PE ratio of -1.55 and a beta of 0.01.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. As a group, equities research analysts predict that Allarity Therapeutics will post -78.08 EPS for the current year.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.